Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blinded, Randomized Controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of N1, N3-bis-(2-Mercaptoethyl) Isophthalamide (NBMI) in the Reduction of Mercury Levels, in Subjects Exposed to Mercury in Colombia

NCT04183595 is registered in ClinicalTrials.gov with EmeraMed as lead sponsor.

NCT NCT04183595
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04183595 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blinded, Randomized Controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of N1, N3-bis-(2-Mercaptoethyl) Isophthalamide (NBMI) in the Reduction of Mercury Levels, in Subjects Exposed to Mercury in Colombia
Lead sponsor
EmeraMed
Phase
Phase 2/3
Overall status
Unknown status
Start date
November 22, 2023
Completion date
November 22, 2024
Enrollment
116 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

mercury poisoning